Shida S, Arioka H, Hatayama Y, Nakadate H, Hatae Y, Takeda T
Dept. of Pediatrics, National Sapporo Hospital.
Gan To Kagaku Ryoho. 1988 Mar;15(3):425-9.
Five patients with advanced neuroblastoma were treated with the protocol of the Welfare Ministry used by the Sawaguchi group. This protocol consists of cyclophosphamide (CPM), vincristine (VCR), 4'-O-tetrahydropyranyladriamycin (THP-ADM) and cisplatinum (CDDP). Two patients treated with this protocol as the first therapy obtained partial remission. Two patients who had obtained complete remission before the treatment with this protocol remained in complete remission after the treatment. One patient who had shown poor response to the therapy given before treatment with this protocol also showed poor response to the protocol. The most significant side effect with this protocol was myelosuppression, the severity of which was closely related to the dose of THP-ADM. Damage to the liver, kidney and heart was not very significant. We advocate that patients with advanced neuroblastoma can obtain complete remission with the aid of surgery and radiotherapy, etc., if they are treated with the present protocol as the first therapy.
5例晚期神经母细胞瘤患者采用泽口组使用的厚生省方案进行治疗。该方案由环磷酰胺(CPM)、长春新碱(VCR)、4'-O-四氢吡喃阿霉素(THP-ADM)和顺铂(CDDP)组成。2例将该方案作为首次治疗的患者获得部分缓解。2例在使用该方案治疗前已获得完全缓解的患者在治疗后仍保持完全缓解。1例在使用该方案治疗前对先前给予的治疗反应不佳的患者对该方案的反应也较差。该方案最显著的副作用是骨髓抑制,其严重程度与THP-ADM的剂量密切相关。对肝脏、肾脏和心脏的损害不太明显。我们主张,如果将目前的方案作为首次治疗,晚期神经母细胞瘤患者借助手术和放疗等手段可获得完全缓解。